IP Library Granted Patent US 9,655,966
Granted Patent B2
US 9,655,966 · App. 12/284,841 · Granted May 23, 2017

Micronutrient formulations for radiation applications

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,655,966
App. No.
12/284,841
Granted
May 23, 2017
Kind
B2
Abstract

A radioactive protection micronutrient formulation system is provided and the system comprises: a formulation consisting essentially of antioxidants, the antioxidants are selected from the group consisting essentially of vitamin C, vitamin E, N-acetyl cysteine, natural mixed carotenoids, and alpha-lipoic acid, vitamin A (palmitate), vitamin D-3 (cholecalciferol), thiamine mononitrate, riboflavin, niacinamide ascorbate, d-calcium pantothenate, pyridoxine hydrochloride, cyanocobalamin, folic acid, D-Biotin, selenium (1-seleno-methionine), chromium picolinate, zinc glycinate, calcium citrate and magnesium citrate and mixtures thereof; and plus a booster formulation selected from a group consisting essentially of vitamin C, d-alpha tocopheryl acid succinate, alpha tocopherol, N-acetyl cysteine, natural mixed carotenoids and alpha lipoic acid, the formulation is designed to reduce the risk in humans exposed to doses of ionizing radiation of becoming subjected to at least one condition selected from the group consisting essentially of radiation-induced acute leukemia, breast cancer, thyroid cancer and other somatic and heritable mutations.

Claims (13)

1. A formulation consisting of antioxidants and a booster formulation, said antioxidants consisting of vitamin C, vitamin E, N-acetyl cysteine, natural mixed carotenoids, alpha-lipoic acid, vitamin A, vitamin D, thiamine mononitrate, riboflavin, niacinamide ascorbate, d-calcium pantothenate, pyridoxine hydrochloride, cyanocobalamin, folic acid, D-Biotin, selenium, chromium picolinate, zinc glycinate, calcium citrate, and magnesium citrate; and

said booster formulation consisting of vitamin C, d-alpha tocopheryl acid succinate, alpha tocopherol, N-acetyl cysteine, natural mixed carotenoids and alpha lipoic acid,

and wherein said formulation is designed to reduce the risk in humans exposed to doses of ionizing radiation of becoming subjected to at least one condition selected from the group consisting of radiation-induced acute leukemia, breast cancer, thyroid cancer and other somatic and heritable mutations caused by radiation exposure.

2. The formulation of claim 1 wherein a dosage level of the antioxidants is proportionate to a radiation level exposed to by the human.

3. The formulation of claim 1 wherein said formulation is designed for a human who receives an effective dose of ionizing radiation of 0.5 mSv or less.

4. The formulation of claim 1 wherein said formulation is designed for a human who receives an effective dose of ionizing radiation of 0.5-5 mSv.

5. The formulation of claim 4 wherein said booster formulation consists of 500 mg of vitamin C, 400 international units of d-alpha tocopheryl acid succinate, 250 mg of N-acetyl cysteine, 15 mg of natural mixed carotenoids, and 30 mg of alpha-lipoic acid and wherein the booster formulation is taken 1 hour prior to an imaging study.

6. The formulation of claim 1 wherein said formulation is designed for a human who receives an effective dose of ionizing radiation of 5-15 mSv.

7. The formulation of claim 6 wherein said booster formulation consists of 500 mg of vitamin C, 400 international units of d-alpha tocopheryl acid succinate, 250 mg of N-acetyl cysteine, 15 mg of natural mixed carotenoids, and 30 mg of alpha-lipoic acid and wherein the booster formulation is taken 24 hours and 1hour prior to an imaging study and 24 hours after the imaging study.

8. The formulation of claim 1 wherein said formulation is designed for a human who receives an effective dose of ionizing radiation of 15-250 mSv.

9. The formulation of claim 8 wherein said booster formulation consists of 500 mg of vitamin C, 400 international units of d-alpha tocopheryl acid succinate, 500 mg of N-acetyl cysteine, 30 mg of natural mixed carotenoids, and 60 mg of alpha lipoic acid and wherein the booster formulation is taken 48 hours, 24 hours and 1 hour prior to an imaging study and 24 hours after the imaging study.

10. A method of manufacturing a formulation of claim 1 , said method comprising admixing the antioxidants and separately admixing the booster formulation.

11. The method of claim 10 wherein a dosage level of the antioxidants is proportionate to a radiation level exposed to by the human.

Assignments (10)
RELEASE OF SECURITY INTEREST Recorded Mar 23, 2022
From: JGB COLLATERAL, LLC
To: NABC, INC.
Reel/Frame 059383/0122 →
RELEASE OF SECURITY INTEREST Recorded Dec 22, 2020
From: EAST WEST BANK
To: NEW AGE BEVERAGES CORPORATION; NEW AGE HEALTH SCIENCES, INC.; MORINDA, INC.
Reel/Frame 054733/0587 →
RELEASE OF SECURITY INTEREST Recorded Dec 7, 2020
From: EAST WEST BANK
To: NEWAGE, INC.; NABC, INC.; MORINDA, INC.
Reel/Frame 054560/0232 →
SECURITY INTEREST Recorded Dec 1, 2020
From: ARIEL MERGER SUB 2, LLC; NEWAGE, INC. (A WASHINGTON CORPORATION); NABC, INC.; MORINDA, INC.
To: JGB COLLATERAL, LLC (A DELAWARE LIMITED LIABILITY COMPANY)
Reel/Frame 054509/0837 →
RELEASE OF SECURITY INTEREST Recorded Apr 4, 2019
From: DOMINION CAPITAL LLC
To: NEW AGE BEVERAGES CORPORATION; NEW AGE HEALTH SCIENCES, INC.
Reel/Frame 048793/0288 →
SECURITY INTEREST Recorded Apr 1, 2019
From: NEW AGE BEVERAGES CORPORATION; NEW AGE HEALTH SCIENCES, INC.; MORINDA, INC.
To: EAST WEST BANK
Reel/Frame 048752/0082 →
RELEASE OF SECURITY INTEREST Recorded Apr 1, 2019
From: SIENA LENDING GROUP LLC
To: NEW AGE BEVERAGES CORPORATION; NEW AGE HEALTH SCIENCES, INC.
Reel/Frame 048752/0034 →
SECURITY INTEREST Recorded Aug 13, 2018
From: NEW AGE BEVERAGES CORPORATION; NEW AGE HEALTH SCIENCES CORPORATION
To: SIENA LENDING GROUP LLC
Reel/Frame 046623/0692 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 9, 2018
From: PREMIER MICRONUTRIENT CORPORATION
To: NEW AGE HEALTH SCIENCES, INC.
Reel/Frame 046599/0450 →
SECURITY INTEREST Recorded Jun 22, 2018
From: NEW AGE BEVERAGES CORPORATION; NEW AGE HEALTH SCIENCES, INC.
To: DOMINION CAPITAL LLC
Reel/Frame 046181/0389 →